Clinical trials: insulin glargine
Type 1 Diabetes Mellitus
Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients
The transition from the Pediatric clinic to the adult care is a challenging period for young adults with type 1 diabetes, due to the high risk of poor glycemic control.
- Trial name
- METRO (NCT03463564)
- Testing
- Insulin pump, Insulin injections
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Campania Luigi Vanvitelli
Diabetes Mellitus, Type 1
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus
- Trial name
- NCT00356421
- Testing
- Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog)
- Where
- 23 sites in United States, Austria and 11 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Diabetes
Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
The investigators anticipate that the use of Glargine will decrease the duration of an insulin drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit) length of stay, improve glycemic control…
- Trial name
- NCT01153100
- Testing
- Glargine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
Primary Objective: To demonstrate the non-inferiority of hemoglobin A1c (HbA1c) control at six months between the basal plus one and the biphasic insulin regimen.
- Trial name
- B to B (NCT01212913)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE, Insulin aspart
- Where
- South Korea
- Volunteers
- 161 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT00961324
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
Primary Objective: To assess the efficacy of Gla-300 on glycemic control measured by hemoglobin A1c (HbA1c) change in patients with type 2 diabetes mellitus (T2DM) uncontrolled with their current basal insulin following the…
- Trial name
- ARTEMIS-DM (NCT03760991)
- Testing
- INSULIN GLARGINE (U300)
- Where
- 14 sites in Argentina, Colombia and 12 more
- Volunteers
- 372 people
- Sponsor
- Sanofi
Hyperglycemia
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is…
- Trial name
- SITA-CABGDM (NCT02556918)
- Testing
- Sitagliptin, Regular Human Insulin, Insulin glargine
- Where
- 3 sites in United States
- Volunteers
- 202 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 1, Healthy Volunteers
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes
This study is investigating the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentrations in the blood and its effect on blood sugar for the treatment of diabetes.
- Trial name
- NCT03965013
- Testing
- NNC0268-0965, insulin glargine
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes
The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes.
- Trial name
- NCT04484779
- Testing
- IIM System, Insulin Lispro and/or Insulin Glargine
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Eli Lilly and Company
Obesity, Type 2 Diabetes
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
The aim of this study is to investigate if endogenous Glucagon Like Peptide -1 (GLP-1) has an effect on brain satiety and reward systems and if there are alterations in obese patients with type 2 diabetes (T2DM).
- Trial name
- LIBRA (NCT01363609)
- Testing
- Liraglutide treatment 12 weeks, insulin glargine treatment, GLP-1 receptor antagonist
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of night time low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 2 (NCT01435616)
- Testing
- Glargine, LY2605541
- Where
- 167 sites in United States, Argentina and 21 more
- Volunteers
- 1,538 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01135992)
- Testing
- insulin degludec, insulin glargine
- Where
- 27 sites in United States
- Volunteers
- 143 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus, Nocturnal Hypoglycemia
Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia
The purpose of this study is to determine whether insulin degludec compared to insulin glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the greatest potential benefit from optimised insulin…
- Conditions
- Type 1 Diabetes Mellitus, Nocturnal Hypoglycemia, Recurrent Severe Hypoglycaemia
- Trial name
- HypoDeg (NCT02192450)
- Testing
- Insulin aspart/glargine, Insulin aspart/degludec
- Where
- Denmark
- Volunteers
- 149 people
- Sponsor
- Nordsjaellands Hospital
Pemphigus Vulgaris, Skin Erosion
Effect of Topical Insulin on Healing Rate of Pemphigus Lesions
This study investigates the efficacy of topical insulin in promoting healing of pemphigus vulgaris erosions. Twenty patients with pemphigus vulgaris were enrolled, each contributing three comparable lesions randomly allocated to…
- Conditions
- Pemphigus Vulgaris, Skin Erosion, Autoimmune Blistering Disease
- Trial name
- NCT07461103
- Testing
- insulin glargine, human insulin, 0.9% Normal Saline
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Alexandria University
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.
- Trial name
- NCT05248841
- Testing
- HEC-Glargine, US-Lantus
- Where
- South Africa
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lannett Company, Inc.
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ V (NCT01952145)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 91 sites in United States, Argentina and 8 more
- Volunteers
- 557 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine
The study will look at the efficacy and safety of NNC0268-0965 (referred to as insulin 965). The study aims to show that insulin 965 has positive effects on the blood vessels.
- Trial name
- NCT04575181
- Testing
- NNC0268-0965, Insulin glargine
- Where
- 2 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
Primary Objective: To test the hypothesis that basal insulin based treatment (G+) is noninferior to twice-daily premixed insulin (PM-2) in term of hemoglobin A1c (glycosylated hemoglobin, HbA1c) reduction from baseline to end of…
- Trial name
- SWITCH (NCT03359837)
- Testing
- INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM
In this prospective, randomized, open-label, parallel group trial, the safety and efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with basal insulin once or twice daily plus pre-prandial insulin…
- Conditions
- Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range
- Trial name
- NCT04965051
- Testing
- insulin degludec/insulin aspart (IDegAsp), basal insulin plus pre-prandial insulin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine